GLS and cancer: For instance, a small-molecule allosteric inhibitor of glutaminase (GLS), CB-839 (Telaglenastat), has been used in clinical trials in combination with paclitaxel specifically for advanced TNBC (NCT03057600), as well as with other chemotherapies (NCT03047993, NCT03798678) and immunotherapies (NCT04265534) for a variety of cancer types.